Clopidogrel

Generic Name
Clopidogrel
Brand Names
Duoplavin, Plavix, Zyllt, Clopidogrel BGR (previously Zylagren), Clopidogrel TAD, Clopidogrel ratiopharm, Clopidogrel Zentiva (previously Clopidogrel Winthrop), Clopidogrel Krka, Clopidogrel Krka d.d. (previously Zopya), Clopidogrel Teva (hydrogen sulphate), Clopidogrel HCS, Iscover, Grepid, Clopidogrel Taw Pharma (previously Clopidogrel Mylan), Clopidogrel Viatris (previously Clopidogrel Taw Pharma)
Drug Type
Small Molecule
Chemical Formula
C16H16ClNO2S
CAS Number
113665-84-2
Unique Ingredient Identifier
A74586SNO7
Background

Clopidogrel is a prodrug of a platelet inhibitor used to reduce the risk of myocardial infarction and stroke. Clopidogrel is indicated to reduce the risk of myocardial infarction for patients with non-ST elevated acute coronary syndrome (ACS), patients with ST-elevated myocardial infarction, and in recent MI, stroke, or established peripheral arterial disease,

It has been shown to be superior to aspirin in reducing cardiovascular outcomes in patients with cardiovascular disease and provides additional benefit to patients with acute coronary syndromes already taking aspirin.

Clopidogrel was granted FDA approval on 17 November 1997.

Indication

1.用于新近心肌梗死、新近脑卒中或确诊的周围动脉病变患者，可减少新的缺血性脑卒中、心肌梗死和死亡等心脑血管事件的符合终点；

2.用于急性冠状动脉综合征（不稳定心绞痛和非ST段抬高心肌梗死）患者；

3.用于冠状动脉支架置入术后预防支架内血栓形成（与阿司匹林联用）。

Associated Conditions
Acute Coronary Syndrome (ACS), Acute Myocardial Infarction (AMI), Cardiovascular Events, Atherothrombotic events
Associated Therapies
-
Clinical Trials
Related News

Ex Vivo Human Thrombosis Chamber Study

Phase 1
Completed
Conditions
Cardiovascular Disease
Interventions
Drug: Clopidogrel
Drug: Aspirin
First Posted Date
2009-07-09
Last Posted Date
2011-02-23
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
15
Registration Number
NCT00935506
Locations
🇺🇸

Mds Pharma Services, Neptune, New Jersey, United States

Tailoring Of Platelet Inhibition to Avoid Stent Thrombosis

First Posted Date
2009-06-05
Last Posted Date
2010-04-13
Lead Sponsor
Uppsala University
Target Recruit Count
450
Registration Number
NCT00914368
Locations
🇸🇪

Uppsala Clinical Research Center, Uppsala, Sweden

Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Prasugrel (TRIGGER-PCI)

First Posted Date
2009-05-29
Last Posted Date
2012-06-08
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
423
Registration Number
NCT00910299
Locations
🇩🇪

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Wuppertal, Germany

Comparison of Platelet Inhibition With Adjunctive Cilostazol Versus High Maintenance-Dose Clopidogrel According to Hepatic Cytochrome 2C19 Allele (CYP2C19) Polymorphism

First Posted Date
2009-05-01
Last Posted Date
2009-05-01
Lead Sponsor
Gyeongsang National University Hospital
Target Recruit Count
80
Registration Number
NCT00891670
Locations
🇰🇷

Gyeong-Sang National University Hospital, Jinju, Gyeong-Nam, Korea, Republic of

Resistance to Antithrombotic Therapy

Not Applicable
Completed
Conditions
Atherosclerosis
Angioplasty
Interventions
Drug: aspirin
Drug: clopidogrel
First Posted Date
2009-03-10
Last Posted Date
2012-12-12
Lead Sponsor
Medical University of Vienna
Target Recruit Count
46
Registration Number
NCT00858715
Locations
🇦🇹

Division of Angiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria

Bleeding Time Study With AZD6482, Clopidogrel and ASA

Phase 1
Completed
Conditions
Antiplatelet Effect
Interventions
Drug: AZD6482
Drug: Clopidogrel
Drug: ASA
First Posted Date
2009-03-02
Last Posted Date
2009-08-19
Lead Sponsor
AstraZeneca
Target Recruit Count
28
Registration Number
NCT00853450
Locations
🇸🇪

Research Site, Lund, Sweden

Clopidogrel Resistance and the Possibility of Its Affection

First Posted Date
2009-02-09
Last Posted Date
2019-02-01
Lead Sponsor
Charles University, Czech Republic
Registration Number
NCT00839345
Locations
🇨🇿

Cardiocenter, Dept. Of Cardiology, Charles University Hospital, Prague, Czechia

Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation

Phase 3
Completed
Conditions
Heart Defects, Congenital
Interventions
Drug: placebo
Drug: Clopidogrel
First Posted Date
2009-02-02
Last Posted Date
2011-08-22
Lead Sponsor
Sanofi
Target Recruit Count
49
Registration Number
NCT00833703
Locations
🇬🇧

Sanofi-Aventis Administrative Office, Guildford Surrey, United Kingdom

A Comparison of Antiplatelet Therapies in Asian Subjects With Acute Coronary Syndrome

Phase 3
Completed
Conditions
Acute Coronary Syndrome
Interventions
Drug: Prasugrel
Drug: Clopidogrel
First Posted Date
2009-01-28
Last Posted Date
2011-11-02
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
720
Registration Number
NCT00830960
Locations
🇹🇭

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Chiang Mai, Thailand

Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty

Phase 2
Completed
Conditions
Platelet Reactivity
Interventions
Drug: Clopidogrel
First Posted Date
2009-01-22
Last Posted Date
2011-04-29
Lead Sponsor
Ottawa Heart Institute Research Corporation
Target Recruit Count
100
Registration Number
NCT00827346
Locations
🇨🇦

University of Ottawa Heart Institute, Ottawa, Ontario, Canada

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy